|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.93 EUR | +0.84% |
|
-1.38% | +9.19% |
| 10/07 | GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial | AN |
| 10/07 | GSK, Hansoh's targeted cancer drug hits main survival goal in China trial | RE |
| Market Cap | 78.16B 105B 91.75B 84.62B 148B 10,004B 151B 1,011B 397B 4,928B 394B 385B 16,942B | P/E 2026 * |
12.4x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 93.45B 125B 110B 101B 177B 11,960B 180B 1,209B 475B 5,892B 471B 461B 20,255B | EV / Sales 2026 * |
2.76x | EV / Sales 2027 * | 2.54x |
| Free-Float |
92.29% | Yield 2026 * |
3.55% | Yield 2027 * | 3.74% |
Last Transcript: GSK plc
| 1 day | +0.84% | ||
| 1 week | -1.38% | ||
| Current month | -0.86% | ||
| 1 month | +2.96% | ||
| 3 months | -7.28% | ||
| 6 months | +5.81% | ||
| Current year | +9.19% |
| 1 week | 22.69 |  | 23.7 |
| 1 month | 22 | | 23.7 |
| Current year | 20.27 | | 26.02 |
| 1 year | 15.35 | | 26.02 |
| 3 years | 14.68 | | 26.02 |
| 5 years | 14.62 | | 27.13 |
| 10 years | 14.62 | | 27.52 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.84% | -1.38% | - | - | 105B | |
| -2.33% | -2.09% | +50.33% | +162.29% | 1,085B | |
| -0.82% | -2.30% | +62.97% | +61.11% | 624B | |
| -0.73% | -4.98% | +27.22% | +84.46% | 442B | |
| +0.33% | -1.17% | +27.98% | +26.90% | 332B | |
| -0.02% | -2.85% | +25.27% | +44.88% | 282B | |
| -3.89% | -11.22% | +20.78% | +26.07% | 277B | |
| +0.66% | -1.42% | -29.26% | -39.30% | 217B | |
| -0.06% | -2.88% | +20.98% | +61.70% | 196B | |
| -3.72% | -1.10% | +13.35% | +71.53% | 167B | |
| Average | -0.72% | -3.56% | +24.40% | +55.51% | 402.44B | |
| Weighted average by Cap. | -0.54% | -3.16% | +35.37% | +81.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.88B 45.47B 39.77B 36.68B 64.29B 4,336B 65.37B 438B 172B 2,136B 171B 167B 7,344B | 35.61B 47.79B 41.8B 38.56B 67.57B 4,558B 68.71B 461B 181B 2,245B 179B 176B 7,719B |
| Net income | 6.52B 8.75B 7.66B 7.06B 12.38B 835B 12.59B 84.38B 33.14B 411B 32.87B 32.15B 1,414B | 7.04B 9.45B 8.27B 7.63B 13.37B 902B 13.59B 91.13B 35.79B 444B 35.5B 34.72B 1,527B |
| Net Debt | 15.29B 20.51B 17.94B 16.55B 29.01B 1,957B 29.49B 198B 77.66B 964B 77.03B 75.35B 3,314B | 12.22B 16.4B 14.35B 13.23B 23.19B 1,565B 23.58B 158B 62.1B 771B 61.59B 60.25B 2,650B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/07/26 | EUR 23.20 | +2.02% | 250 |
| 09/07/26 | EUR 22.74 | -0.61% | 525 |
| 08/07/26 | EUR 22.88 | -1.34% | 220 |
| 07/07/26 | EUR 23.19 | -0.13% | 237 |
| 06/07/26 | EUR 23.22 | -0.13% | 2,372 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GS71 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
